Korro Bio to Showcase RNA Editing Data Across Key Conferences

Event summary

  • Korro Bio will present data on its OPERA® RNA editing technology at five scientific conferences between April 22 and May 30, 2026.
  • Key presentations include KRRO-121 data for hyperammonemia and RNA editing for Alpha-1 Antitrypsin deficiency (AATD).
  • Chief Scientific Officer Loïc Vincent will discuss platform innovations at TIDES USA 2026 on May 14.
  • Poster sessions cover ALS disease models and novel triplet chemistries expanding the OPERA® platform.

The big picture

Korro Bio's conference presentations highlight its focus on RNA editing for both rare and prevalent diseases, positioning it in the competitive landscape of genetic medicines. The company's oligonucleotide-based approach leverages established delivery modalities, potentially offering advantages in specificity and tolerability. These presentations come as the biopharmaceutical industry increasingly turns to RNA-based therapies for conditions previously considered undruggable.

What we're watching

Clinical Translation
Whether preclinical hyperammonemia data for KRRO-121 will accelerate human trials.
Platform Scalability
The pace at which Korro can expand its OPERA® platform capabilities through novel chemistries.
Competitive Positioning
How Korro's RNA editing approach differentiates it in the crowded genetic medicines space.